Ongoing Clinical Trials for Lipid Metabolism Disorder
There is currently 1 ongoing clinical trial investigating new treatment options for lipid metabolism disorder. This trial focuses on testing an investigational medication called AZD0780 for managing abnormal cholesterol levels in adults with dyslipidemia, a common type of lipid metabolism disorder. The study is being conducted across multiple European countries and aims to evaluate how this new treatment affects “bad” cholesterol levels compared to placebo.
Clinical trial locations
- Czechia
- Denmark
- Hungary
- Slovakia
- Spain
Study on the Effects of AZD0780 on Cholesterol Levels in Adults Aged 18-75 with Dyslipidemia
This trial is investigating a new medication called AZD0780 for the treatment of dyslipidemia, a condition characterized by abnormal levels of fats such as cholesterol in the blood. The main focus is on reducing low-density lipoprotein cholesterol, commonly known as “bad cholesterol,” which contributes to heart disease and stroke risk when levels are too high.
Main inclusion criteria:
- Adults aged between 18 and 75 years old
- Fasting LDL-C levels between 70 and 190 mg/dL at the study start
- Fasting triglyceride levels below 400 mg/dL
- Currently taking moderate or high-intensity statin medication for at least 2 months before joining the study
- No planned changes to current cholesterol medications during the study period
- Body mass index of at least 19.0 kg/m²
Main exclusion criteria:
- Serious medical conditions that could interfere with the study
- Pregnancy or breastfeeding
- Participation in another clinical trial within the past 30 days
- History of allergic reactions to the study medication
- Uncontrolled high blood pressure
- Severe liver or kidney disease
- History of drug or alcohol abuse
- History of heart disease, including heart attack or stroke
- Taking medications that might interfere with the study drug
Study focus and procedure: The trial will last for 12 weeks. Participants will be randomly assigned to receive either AZD0780 or a placebo in the form of a film-coated tablet taken orally. Neither participants nor study staff will know who receives the active medication or placebo. Throughout the study, regular follow-up visits will monitor changes in cholesterol levels through blood tests, assess vital signs, and evaluate any side effects. The goal is to determine whether AZD0780 can effectively and safely lower bad cholesterol levels in people who are already taking statins.
Investigational drug: AZD0780 is an experimental oral medication designed to lower LDL-C levels by targeting specific pathways in the body. It belongs to the class of lipid-lowering agents and is being studied for its potential to provide an additional treatment option for managing cholesterol levels in people with dyslipidemia. The medication is still in the experimental phase and is not yet approved as a standard treatment.
Summary
Currently, there is one clinical trial available for people with lipid metabolism disorder, specifically targeting dyslipidemia with abnormal cholesterol levels. The trial is being conducted across five European countries: Slovakia, Spain, Denmark, Hungary, and Czechia, offering opportunities for patients in these regions to access investigational treatment.
The study focuses on AZD0780, a new oral medication aimed at reducing bad cholesterol levels in adults already taking statin therapy. The 12-week trial will evaluate both the effectiveness of different doses of this medication in lowering LDL-C and its safety profile. This research is particularly relevant for patients whose cholesterol levels remain elevated despite current treatment with statins, potentially offering a new therapeutic option for cardiovascular disease prevention.
The trial includes careful monitoring throughout the treatment period to ensure patient safety and to gather comprehensive data on how the medication affects cholesterol levels and overall health.